SCHEMBL5007929

SCHEMBL5007929

COC1=CC(c2ccc(Cl)cc2)=N/C1=C/c1[nH]c(C)cc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 2/20 0.39
ASPH Q12797 2/20 0.39
BCL2 P10415 1/20 0.39
ADORA1 P30542 1/20 0.39
MCL1 Q07820 1/20 0.39
BCL2A1 Q16548 1/20 0.39
BCL2L2 Q92843 1/20 0.39
BAD Q92934 1/20 0.39
BCL2L10 Q9HD36 1/20 0.39
RET P07949 6/20 0.38
CHEK1 O14757 1/20 0.34
KDR P35968 7/20 0.33
GCGR P47871 1/20 0.31
MAPK14 Q16539 1/20 0.31
FLT3 P36888 3/20 0.31
ALK Q9UM73 3/20 0.31
ABL1 P00519 2/20 0.31
ALOX5 P09917 3/20 0.31
CSF1R P07333 2/20 0.30
FGFR1 P11362 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5007931 1.00 BCL2L1 (0.39) BCL2L1ASPHBCL2ADORA1MCL1
SCHEMBL5007903 0.88 BCL2L1 (0.39) BCL2L1ASPHBCL2ADORA1MCL1
SCHEMBL4998204 0.88 BCL2L1 (0.39) BCL2L1ASPHBCL2ADORA1MCL1
SCHEMBL4998209 0.88 BCL2L1 (0.39) BCL2L1ASPHBCL2ADORA1MCL1
SCHEMBL15468683 0.88 BCL2L1 (0.39) BCL2L1ASPHBCL2ADORA1MCL1
SCHEMBL14008562 0.88 BCL2L1 (0.39) BCL2L1ASPHBCL2ADORA1MCL1
SCHEMBL4043315 0.88 BCL2L1 (0.45) BCL2L1ASPHBCL2ADORA1MCL1
SCHEMBL14008571 0.88 BCL2L1 (0.45) BCL2L1ASPHBCL2ADORA1MCL1
SCHEMBL4043318 0.88 BCL2L1 (0.45) BCL2L1ASPHBCL2ADORA1MCL1
SCHEMBL4053031 0.86 BCL2L1 (0.38) BCL2L1ASPHBCL2ADORA1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836165-B1 DIPYRROLE COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES GEMIN X PHARMACEUTICALS CANADA INC (CA) 2014-02-12 EP claimed
US-8420693-B2 Prevent replication or infection from virus; antiproliferative agent; screening analysis GEMIN X PHARMACEUTICALS CANADA INC. (CA) 2013-04-16 US claimed
US-20080280896-A1 Dipyrrole Compounds, Compositions, and Methods For Treating Cancer or Viral Diseases GEMIN X BIOTECHNOLOGIES INC. (CA) 2008-11-13 US claimed
EP-1836165-B1 DIPYRROLE COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES GEMIN X PHARMACEUTICALS CANADA INC (CA) 2014-02-12 EP disclosed
US-8420693-B2 Prevent replication or infection from virus; antiproliferative agent; screening analysis GEMIN X PHARMACEUTICALS CANADA INC. (CA) 2013-04-16 US disclosed
US-20080280896-A1 Dipyrrole Compounds, Compositions, and Methods For Treating Cancer or Viral Diseases GEMIN X BIOTECHNOLOGIES INC. (CA) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280896-A1 Dipyrrole Compounds, Compositions, and Methods For Treating Cancer or Viral Diseases ZC3HAV1, DPEP1, ING2 BCL2L1 1867/4885ASPH 507/4885BCL2 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.